CIPO Patents = 3

EPO Patents = 1

Forward Citations = 0

Loading Chart...

7 inventors (with patents filed for the assignee):

Richard B Silverman (4 out of 108 patents)

Donald R Kirsch (4 out of 5 patents)

Radhia Benmohamed (4 out of 5 patents)

4. Anthony C Arvanites (4 out of 5 patents)

5. Richard I Morimoto (4 out of 7 patents)

6. Wei Zhang (3 out of 4 patents)

7. Tian Chen (1 out of 1 patent)

8. Guoyao Xia (1 patent)

9. Tian Chen (0 patent)

4 patents: Sort by Forward Citations

1. 10167263 - Treatment of amyotrophic lateral sclerosis (2019-01-01),

2. 9593069 - Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis (2017-03-14),

3. 9162968 - Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis (2015-10-20),

4. 8722939 - Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis (2014-05-13),

Company Overview

Cambria Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on researching and developing innovative therapies for serious and life-threatening medical conditions. With a strong commitment to improving patient outcomes, Cambria leverages cutting-edge technologies and groundbreaking research to deliver safe and effective treatments to those in need.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

4 Patents

#411 in Cambridge, MA

#3,312 in Massachusetts

#60,597 in US

Cambridge, MA, United States of America

Cambria Pharmaceuticals, Inc.

Forward Citations = 0

7 inventors:

Richard B Silverman (4 out of 108 patents)

Donald R Kirsch (4 out of 5 patents)

Radhia Benmohamed (4 out of 5 patents)

4. Anthony C Arvanites (4 out of 5 patents)

5. Richard I Morimoto (4 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cambria Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/cambria-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]